Immune cells plus a targeted pill for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment for advanced non-small cell lung cancer that has stopped responding to a targeted pill (EGFR-TKI). It combines your own immune cells, grown in a lab, with another targeted pill to try to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery for non-small cell lung cancer and a test showed an EGFR mutation.
- Your cancer has grown or spread after taking an EGFR-TKI pill, and you have refused chemotherapy or other treatments.
- You can provide about 5 tumor samples through a procedure (surgery, biopsy, or bronchoscopy).
- You are generally healthy enough for daily activities (ECOG score 0-2), with adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a treatment using your own immune cells (called TILs) to fight multiple early-stage lung cancers. The cells are collected from a tumor sample, grown in a lab, and given back to you to help your body attack the cancer.
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
Hear when a new EGFR-TKI-resistant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.